Upstream Bio, Inc. (UPB)

NASDAQ: UPB · Real-Time Price · USD
26.38
-0.42 (-1.57%)
Nov 12, 2024, 4:00 PM EST - Market closed
-1.57%
Market Cap 1.41B
Revenue (ttm) 2.21M
Net Income (ttm) -69.59M
Shares Out 53.60M
EPS (ttm) -24.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 161,371
Open 26.76
Previous Close 26.80
Day's Range 25.80 - 26.76
52-Week Range 20.74 - 29.46
Beta n/a
Analysts Strong Buy
Price Target 56.50 (+114.18%)
Earnings Date Nov 7, 2024

About UPB

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2024
Employees 38
Stock Exchange NASDAQ
Ticker Symbol UPB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for UPB stock is "Strong Buy." The 12-month stock price forecast is $56.5, which is an increase of 114.18% from the latest price.

Price Target
$56.5
(114.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.

7 days ago - Benzinga

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on sev...

4 weeks ago - GlobeNewsWire

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

4 weeks ago - Reuters

Upstream Bio raises $255 mln in US IPO

Upstream Bio , which is developing treatments for some respiratory disorders, said on Thursday it had raised $255 million in its initial public offering in the United States.

4 weeks ago - Reuters

Upstream Bio Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on sev...

4 weeks ago - GlobeNewsWire

Respiratory disorder biotech Upstream Bio files for a $100 million IPO

Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.

7 weeks ago - Renaissance Capital

Upstream Bio IPO Registration Document (S-1)

Upstream Bio has filed to go public with an IPO on the NASDAQ.

7 weeks ago - SEC